Skip to main content
Premium Trial:

Request an Annual Quote

Singapore's GIS Taps BT Group's Cloud for NGS Analysis

NEW YORK (GenomeWeb) – A*STAR's Genome Institute of Singapore (GIS) has tapped the BT Group's cloud compute infrastructure to support its existing genome analysis capabilities.

Under the terms of the agreement, GIS will have access to the BT Cloud Compute infrastructure, which is built on the BT for Life Sciences platform, and will use the system to run compute-intensive workloads. It will help GIS speed up efforts to develop commercial and clinical applications for analyzing NGS data as well as efforts to develop algorithms that can be used to explore disease etiologies, GIS Executive Director Ng Huck Hui said in statement.

GIS Chief Scientific Computing Officer Fu Zhiyan added that the deal "extends our in-house infrastructure to support surges in computational demand" and can also "deliver GIS's algorithms to researchers worldwide and enrich the institute's contributions to global research collaborations."

Financial and other terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.